BETH ISRAEL DEACONESS MEDICAL CENTER;ACCELERON PHARMA INC.
发明人:
BHATT, RUPAL S.,KUMAR, RAVINDRA,MIER, JAMES W.,PEARSALL, ROBERT,SHERMAN, MATTHEW,SOLBAN, NICOLAS
申请号：
EP13744185
公开号：
EP2809335A4
申请日:
2013.02.01
申请国别(地区):
EP
年份:
2015
代理人:
摘要：
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit tumor growth of renal cell carcinoma (RCC) in vivo. In additional aspects the disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of ALK1 dramatically increases the ability of a standard of care receptor tyrosine kinase inhibitor to inhibit RCC tumor growth in vivo.
